Renal survival and prognostic factors in patients with PR3tibodies (ANCA), which are either directed to myeloper-ANCA associated vasculitis with renal involvement. oxidase (MPO) or proteinase 3 (PR3) [1-3]. These dis-Background. Severe renal disease is a feature of anti-neutroeases can occur in any organ system but the respiratory phil cytoplasmic antibodies (ANCA)-associated small-vessel tract and the kidneys are most frequently involved. Unvasculitis. We evaluated patient and renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with treated, WG results in death within weeks to months. renal involvement at diagnosis during long-term follow-up. Since the introduction of cyclophosphamide and predni-Methods. Eighty-five patients were diagnosed between 1982 solone as standard treatment, survival has improved draand 1996 and followed until 2001 allowing Ն5 years of followmatically from less than 20% at one year reported in up. All patients were treated with prednisolone and cyclophosphamide. Univariate and multivariate analyses with patient 1958 [4] to at least a 60% five-year survival reported in and renal survival as dependent variables were performed.
cyclophosphamide and prednisolone is associated with dialysis dependent at diagnosis, two remained dependent and two again became dialysis dependent after less than one year; severe morbidity and mortality, both at short-term and nine died early without renal recovery. Risk factors for death during long-term follow-up. Initiating aggressive immuoccurring within one year in univariate analysis (RR, 95% CI) nosuppressive therapy in order to regain or conserve were age Ͼ65 years (6.5, 1.6-13.7) and dialysis dependency at independent renal function in patients with ANCA-assodiagnosis (3.6, 1.0-13). Twenty patients died beyond one year during the long-term follow-up. Male gender (4.7, 1.6-10) and ciated vasculitis with renal involvement is, therefore, dedeveloping dialysis dependency during follow-up (4.1, 1.4-12) pendent on the perceived prognosis of the patient. Previwere associated with poor outcome. Risk factor for renal failure ous studies have associated serum creatinine [9, 10] and within one year was dialysis dependency at diagnosis (29, 3.6kidney biopsy findings [9] [10] [11] [12] at diagnosis, and the occur-229). Of 64 patients dialysis independent one year after diagnosis, 12 patients became dialysis dependent during follow-up. A rence of renal relapses [13] with reduced renal survival renal relapse was strongly associated with development of renal in patients with pauci-immune necrotizing glomerulonefailure in long-term follow-up (17, 3.5-81).
phritis. Recently, we and others observed differences
Conclusions. Early death and failure to recover renal funcbetween groups associated with the different antigenic tion in PR3-ANCA associated vasculitis is associated with age Ͼ 65 years and dialysis dependency at diagnosis. Long-term specificity of ANCA [reviewed in 14]. Previously, we renal survival is determined by renal relapses during follow-up studied the long-term outcome in patients with MPOonly. Slow, progressive renal failure without relapses is rarely ANCA associated glomerulonephritis and found that observed in this group. proteinuria at diagnosis and during follow-up was the most important risk factor for the development of renal insufficiency [15] . Thus far, to our knowledge none of Small vessel vasculitides, such as Wegener's granulothe studies have focused on long-term outcome of pamatosis (WG) and microscopic polyangiitis (MPA), are tients with PR3-ANCA associated vasculitis with renal strongly associated with anti-neutrophil cytoplasmic aninvolvement.
In the present study, we retrospectively analyzed papredictors of outcome at diagnosis and during followup, and examined the role of non-renal and renal relapses  2003 by the International Society of Nephrology on long-term survival and renal outcome in this patient titer [16] were determined, microscopic urinalysis was performed, and proteinuria and creatinine were deter-population.
mined in a 24-hour urine collection.
METHODS

Definitions Patients
Remission was defined as a stabilization or improvement of creatinine clearance in combination with the We retrospectively identified all consecutive patients diagnosed with, treated and followed in our hospital for absence of glomerular erythrocyturia and erythrocyte cell casts and symptoms or signs attributable to active PR3-ANCA positive vasculitis with evidence of renal involvement (as determined by a biopsy showing necro-extrarenal vasculitis with CRP Ͻ10 mg/L. A non-renal relapse was defined as new or recurrent findings indica-tizing and/or crescentic glomerulonephritis [1] and/or by deterioration of renal function with glomerular erythro-tive of vasculitic disease without signs of renal involvement [17] . A renal relapse was defined either histopatho-cyturia, erythrocyte casts and proteinuria) between January 1982 and January 1996. Patients were followed until logically by the presence of new necrotizing lesions in a renal biopsy or clinically by recurrence of microscopic January 2001. Surviving patients thus were followed for at least five years.
glomerular erythrocyturia, erythrocyte cell casts, proteinuria and a decrease in creatinine clearance in a pa-Treatment and follow-up tient with a previously stable renal function [17] . Microscopic glomerular erythrocyturia was defined as 10 or Patients were treated according to a standardized protocol [15] . The treatment consisted of oral cyclophospha-more red blood cells, with more than 50% dysmorphic cells, per high power field (magnification ϫ400) in the mide (2 mg/kg) and prednisolone (1 mg/kg body weight) daily with a maximal oral prednisolone dose of 60 mg/ absence of a urinary tract infection or an indwelling catheter. day. Doses of cyclophosphamide were adjusted to maintain the leukocyte count above 4 ϫ 10 9 /L. Patients who Statistical analyses presented with severe vasculitic manifestations such as alveolar hemorrhage, rapidly rising serum creatinine or Data are presented as mean Ϯ standard deviation unless stated otherwise. Continuous data between groups gastrointestinal symptoms were initially treated with intravenous methylprednisolone 1000 mg daily for three were compared using the Student t test and the Wilcoxon signed rank test when appropriate. Survival curves for days. Plasma exchange was added to the treatment regimen in case of disease progression or persistence of ac-patient and renal survival were calculated using Kaplan-Meier estimates for survival distribution. End point for tive disease. The latter was defined as persistence of major extrarenal symptoms or the presence of active renal survival analysis was the start of renal replacement therapy or death due to renal failure. Differences be-necrotizing renal lesions in a repeat renal biopsy after two to four weeks of immunosuppressive therapy. After tween groups in survival were analyzed with log-rank test, and multivariate analysis with Cox proportional haz-four to six weeks, the daily prednisolone dose was tapered by 10 mg every two weeks until the dose reached ards analysis with survival time as dependent variable was performed. Renal survival rates [survival without 30 mg, and thereafter by 5 mg every two to four weeks. Once remission was achieved the daily dose of oral cyclo-end-stage renal disease (ESRD)] are calculated and analyzed with subjects dying with independent renal func-phosphamide was tapered by 25 mg every three months. Patients who experienced a renal relapse, or a life-threat-tion censored. Analyzing patient and renal survival, a large difference ening non-renal relapse, were treated according to the same protocol. Minor non-renal relapses were treated between both patient and renal survival Յ1 year and Ͼ1 year after diagnosis became apparent. Survival differ-with 1 mg/kg body weight cyclophosphamide daily and a maximal oral prednisolone dose of 40 mg/day. ences between groups, therefore, were analyzed separately for the time periods Յ1 year and Ͼ1 year after Patients were hospitalized for at least two to three weeks or longer when indicated. After discharge, pa-diagnosis (long-term follow-up), to identify risk factors for these specific time periods. Independent variables tients visited our outpatient clinic at least every two weeks during the first three months after diagnosis, every tested in the analysis of patient and renal survival Յ1 year were age, gender, pulmonary involvement (with or four weeks until one year after diagnosis, and every six weeks thereafter. At each visit, patients were evaluated without need for mechanical ventilation), CRP level, serum creatinine level, dialysis dependency, and Bir-by the same physician for signs and symptoms of vasculitic disease and/or adverse effects of the treatment. In mingham Vasculitis Activity Score (BVAS) [18] at diagnosis. Variables additionally tested for their association addition, blood pressure (BP) and weight were measured, serum creatinine, erythrocyte sedimentation rate with long-term patient and renal survival (Ͼ1 year) were the occurrence of non-renal and renal relapses, cumula-(ESR) and C-reactive protein (CRP) levels, and ANCA with a relative risk (RR) of 6.5 (95% CI, 1.6-13.7) and 4.0 (1.4-10.5), respectively. Severe renal involvement was also associated with death within one year (dialysis dependency at diagnosis: RR 2.9 [1.3-10.8]; serum creatitive doses of medication, mean arterial pressure (MAP), nine Ͼ500 mol at diagnosis: RR 2.2 [0.9-6.9]). In multicreatinine clearances and proteinuria at 12 months and variate analysis, CRP level at diagnosis, age, and dialysis use of angiotensin converting enzyme (ACE) inhibitors.
dependency at diagnosis were associated with mortality In multivariate analysis the occurrence of non-renal and Յ12 months (Table 3 ). renal relapses were tested as time-dependent variables. Analyses were performed with SPSS version 10.0 (SPSS Independence of renal replacement therapy at one Inc., Chicago, IL, USA). A two-sided P value Ͻ0.05 was year or less considered to indicate statistical significance.
Of the 25 patients who were dialysis-dependent at diagnosis, two did not regain renal function (8%) but RESULTS survived at one year and nine patients (36%) died within Between April 1982 and January 1996, 85 patients one year (median 1 month, range 4 days to 5 months) (55 male, 30 female) were diagnosed with PR3-ANCA without regaining independent renal function. Of 14 papositive vasculitis with renal involvement in our hospital. tients (56%) who regained independent renal function, In all patients, a diagnosis of small-vessel vasculitis was two were only temporarily dialysis-independent and confirmed by biopsy. Renal involvement was confirmed needed dialysis again within one year; one died within in 64 by renal biopsy; in the remaining patients renal 12 months. Only 11 of 25 dialysis-dependent patients at failure, erythrocyturia and erythrocyte casts, and prodiagnosis (48%) were alive at 12 months with a functeinuria was present. Age at diagnosis was 56 Ϯ 17 years. tional renal status. In these 11 patients creatinine clear-Twenty-five patients (29%) were dialysis dependent at ance at 12 months after diagnosis was 38 Ϯ 14 mL/min. diagnosis. Forty-seven patients (55%) had pulmonary Only one of 60 patients who were dialysis-independent at involvement, of whom nine patients (19%) needed mediagnosis (2%) developed renal failure requiring dialysis chanical ventilation. Organ manifestations are presented therapy within one year after diagnosis. With univariate in Table 1 . and multivariate analysis dialysis dependency at diagnosis (RR 29, 95% CI 3.6-229) was the only variable associ-Overall ated with persistent or renewed dialysis dependency For the entire group of 85 patients, estimated patient within one year after diagnosis (Table 4 ). survival at 5 and 10 years was 73 and 62%, respectively (Fig. 1) . Causes of death are presented in Table 2 . Esti-Long-term patient survival mated median survival was significantly shorter in pa-Of 68 patients alive at one year, 27 patients (40%) did tients Ͼ65 years at diagnosis (3.6 years) when compared not relapse, 10 patients (15%) experienced only nonto those Ͻ51 years (17.8 years) and those 51 to 65 years renal relapses, and 31 patients (46%) had at least one of age (17.0 years; P Ͻ 0.0001; Fig. 2 ). The estimated renal relapse, of whom 10 also had one or more non-renal median survival for patients who were dialysis dependent relapses. All relapses were accompanied by the presence at diagnosis was also significantly shorter than survival of PR3-ANCA at the time of relapse. The median time in patients who were not on dialysis (9.4 vs. 17.0 years, to the first non-renal relapse was 3.3 years (range 1.6 to respectively; P ϭ 0.013; Fig. 3 ). Survival with indepen-10.5). The median time to the first renal relapse was 4.3 dent renal function was 65% at 5 years and 51% at 10 years (range 0.8 to 12.2). Twenty patients died more than years (Fig. 1) .
one year after diagnosis. In univariate analysis, age Ͼ65 Mortality within one year years at diagnosis was associated with mortality beyond one year of follow-up compared to age Ͻ51 (RR 10.5, Of the 85 patients, 17 patients (20%) died within one year. The main causes of death were active vasculitis, 3.6 to 51) and age 51 to 65 (RR 2.9, 1.3 to 11), as was . In contrast, non-renal relapses were not associated with reduced renal survival (P ϭ 0.98). Dialysis dependency at diagnosis also was not associated with the development of ESRD in long-term follow-up. male gender (RR 4.7, 1.6 to 10). In multivariate analysis, development of dialysis dependency was additionally as-Influence of non-renal and renal relapses on sociated with death, but occurrence of renal or non-renal renal function relapses was not (Table 3) .
We further analyzed the influence of renal and non-Long-term renal survival renal relapses on renal function by comparing creatinine clearance and proteinuria before, at the moment of, and Of 68 patients alive one year after diagnosis, 64 were following a first relapse. In addition, the slope of the dialysis independent with a creatinine clearance of 64 Ϯ change in creatinine clearance over time was calculated 31 mL/min (median 60 mL/min, range 18 to 142 mL/ until three months before the relapse and compared with min) and proteinuria 0.8 Ϯ 1.0 g/24 h (median 0.3 g/24 h, the slope starting three months after a relapse. In 31 range 0 to 5 g/24 h) at one year. Mean MAP was 101 Ϯ patients with a first renal relapse, creatinine clearance 10 (median 100, range 83 to 127) at one year and did not at the moment of relapse had decreased by 15 Ϯ 13.0 change throughout the study period (data not shown). mL/min compared to 12 months before relapse. At 12 Forty-four patients (65%) were treated with antihypermonths following the first renal relapse clearance was tensives, of which 24 were on ACE-inhibitor and/or anstill 11 Ϯ 11.0 mL/min lower than 12 months before the giotensin II antagonist. Twelve of 64 patients (19%) who relapse (Fig. 4A ). Proteinuria increased from 0.9 Ϯ 1.2 were dialysis independent at one year progressed to g/24 h 12 months before, to 2.0 Ϯ 1.6 g/24 h at, and 1.1 Ϯ ESRD during the study period; the median time to 1.1 g/24 h 12 months after relapse (Fig. 4B ). The slopes ESRD in those 12 patients was 4.3 years after diagnosis of the change in creatinine clearance, excluding the four (range 2.0 to 10.4 years). Five patients who had to start patients who became dialysis dependent at their first renal replacement therapy (RRT) with the occurrence renal relapse, tended to be more negative following as of a renal relapse (4 patients at the first renal relapse, 1 at the third) did not regain renal function during treat-compared to prior to a renal relapse (Ϫ1.8 Ϯ 4.5 mL/ min/year before and Ϫ3.1 Ϯ 5.2 mL/min/year after renal renal involvement during long-term follow-up. Age Ͼ65 years and dialysis dependency at diagnosis were indicarelapse; P ϭ 0.06). In contrast, a first non-renal relapse tive of both poor patient and renal survival. In our longwas not associated with renal function loss or increased term follow-up analysis, renal function deteriorated durproteinuria at the moment of or following the relapse ing and after a renal relapse, and the occurrence of a (Fig. 4) . The slopes of the change in creatinine clearance renal relapse was the only predictor of an unfavorable after the first non-renal relapse were not different before long-term renal prognosis. and after a non-renal relapse (Ϫ1.3 Ϯ 2.0 mL/min/year
The patient survival in our study is comparable to before and Ϫ0.4 Ϯ 1.5 mL/min/year after non-renal reprevious studies considering patients with small-vessel lapse).
vasculitides with renal involvement where it varied from 59 to 95% in various patient groups during various fol-DISCUSSION low-up periods [5, 6, 8, 10, 12, 13, 15, 19] . The mortality The present study evaluated patient and renal survival rate in our series may be somewhat higher as our department is a tertiary referral center and patients with severe in 85 patients with PR3-ANCA associated vasculitis with disease at diagnosis are referred to our hospital, while patients with less severe disease are often managed at their primary hospital. Mortality shortly after diagnosis is mostly due to uncontrolled vasculitis, while the other important cause is severe infectious complications of the treatment, usually occurring within three to six months after the initiation of treatment. These findings clearly highlight the dilemma the clinician treating these patients must face. Prognostic tools in this respect are therefore important to guide the intensity of treatment. Unfortunately, as reported by others [5, 7, 10, 13, 19], early mortality is strongly associated with older age and more advanced organ dysfunction caused by the vasculitic process. Our results showed that dialysis dependency at survival curve, mortality in the first year after diagnosis is different compared to follow-up beyond one year. Therefore, we chose to perform separate analyses for the time periods within and beyond one year after diagoutcome, as described previously [12, 19, 20] . However, nosis. For long-term patient survival, no association of of the 25 patients who were dialysis-dependent at diagnomortality was found with active vasculitis defined as the sis and regained independent renal function, 11 regained occurrence of a non-renal or renal relapse; no patients renal function and they had a mean creatinine clearance died from active vasculitis beyond one year. Long-term of 38 mL/min at one year after diagnosis. We found mortality was associated with advanced age (as reported that dialysis dependency at diagnosis, and not the serum previously [7, 8, 10, 20] ), male gender and development creatinine level, was associated with the development of of need for dialysis during follow-up.
ESRD, which is in contrast to other studies [8-10, 21]. Fourteen patients (16%) developed ESRD during fol-Renal function at one year after diagnosis was associated low-up (2 of whom within one year), and two patients with progression to ESRD for patients who experienced did not recover from dialysis. Dialysis dependency at a renal relapse during follow-up. In long-term follow-up, it does seem that relatively diagnosis was highly associated with unfavorable renal
